Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2022

  • Report Code : 368307
  • Pages : 172
  • Published On : Jan 2018
  • Industry : Healthcare and Pharmaceuticals
  • Format : WMR PPT FormatWMR PDF Format

Choose License Type

Single User License: US$ 2,400
Multi User License: US$ 0
Corporate User License: US$ 3,000
Executive Summary

The report presents the market potential of seven major pipeline drugs meant for the treatment of migraine. These seven drugs that fall in the various categories of Ergotamines, Anti 5-HT Receptor Agonists and Anti-CGRPs by mechanism of action have been recognized as being clinically effective in migraine treatment. Expected to be launched in the market within the next 4-5 years, these seven potential drugs are likely to bring about major changes in the way migraine is treated globally.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Migraine Pipeline Drugs Market by assessing the potential of the seven drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the seven drugs, the product profile, description and regulatory phase of each of the seven drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the seven drugs to present the current perspective.

The report titled "Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2022" also analyzes the overall sizing, growth and forecast of Migraine Drugs Market By Type (Acute and Prophylaxis) for the global market as well as for countries including United States, United Kingdom, Japan, France, Italy and Germany.

Over the recent years, the Migraine Drugs market is growing rapidly due to rising prevalence of migraine patients around the world. Globally, the growth of Migraine Drugs market is driven by rising awareness regarding migraine and available treatments

The global migraine drugs market is projected to display a robust growth represented by a CAGR of 14.48% during 2017- 2022, chiefly driven by rising consumption of unhealthy food coupled with unmet need By the present drugs for the treatment of migraine. The report has covered and analysed the present migraine drugs in the market and has also analysed potential of seven major pipeline drugs. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global migraine pipeline drugs market.

Scope of the Report

Migraine Pipeline Drugs Assessment - Drug X1, X2, X3, X4, X5, X6, X7 (Forecast Period: 2019-2022)
- Market Potential
- Clinical Trials
- Product Description
- Regulatory Phases
- 7Ps Analysis

Global Migraine Drugs Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)
- Market Sizing and Growth
- Market Sizing and Growth By Type - Acute and Prophylaxis

Country Analysis US, UK, Japan, France, Italy, Germany (Actual Period: 2012-2016, Forecast Period: 2017-2022)
- Market Sizing and Growth

Other Report Highlights
- Market Dynamics - Drivers, Challenges
- Company Analysis - Amgen Biopharmaceuticals, Allergan, Eli Lilly, Alder Pharmaceuticals, Teva Pharmaceutical, Vernalis, Pfizer, Impax Laboratories, Glaxo Smithkline

Customization of the Report

The report could be customized according to the client s specific research requirements. No additional cost will be required to pay for limited additional research.
Table of Contents 1. Research Methodology 2. Executive Summary 3. Migraine - An Overview 3.1. Symptoms of migraine 3.2. Stages of Migraine 3.3.Types of Migraine 3.4. Types of migraine on the basis of frequency of occurrence 4. Treatment of Migraine 4.1. Goal of Migraine Treatment 4.2. Treatment of Migraine - Pharmacological and Non-Pharmacological 4.2.1. Pharmacological treatment of migraine 4.2.2. Pharmacological - Abortive 4.2.3. Pharmacological - Preventive 4.2.4. Non-Pharmacological Treatment of Migraine 4.2.5. Non- Pharmacological - Surgical 4.2.6. Non- Pharmacological - Non-Surgical 5. Anti-Migraine Pipeline Drugs Analysis 5.1. Anti-Migraine Pipeline Drugs (According to Mechanism of Working) 5.2. Anti-Migraine Pipeline Drugs (Ergotamine): Drug - X1 5.2.1. Description 5.2.2. Regulatory Milestones 5.2.3. Advantages & Disadvantages 5.2.4. Product Profile & Expected Launch 5.2.5. Clinical Trials and Status 5.2.6. Pivotal Clinical Trials and Results 5.2.7. Drug X-1- Global Market Potential 5.2.8. Drug X-1- 7Ps Analysis 5.3. Anti-Migraine Pipeline Drugs (Anti-5HT Receptor Agonist): Drug - X2 5.3.1. Description 5.3.2. Regulatory Milestones 5.3.3. Advantages & Disadvantages 5.3.4. Product Profile & Expected Launch 5.3.5. Clinical Trials and Status 5.3.6. Pivotal Clinical Trials and Results 5.3.7. Drug - X2 - Global Market Potential 5.3.8. Drug - X2 - 7Ps Analysis 5.4. Anti-Migraine Pipeline Drugs (Anti CGRPs) 5.5. Anti-Migraine Pipeline Drugs (Anti CGRPs) - By Drug 5.6. Anti-Migraine Pipeline Drugs (CGRP Antagonist): Drug - X3 5.6.1. Description 5.6.2. Regulatory Milestones 5.6.3. Advantages & Disadvantages 5.6.4. Product Profile & Expected Launch 5.6.5. Clinical Trials and Status 5.6.6. Pivotal Clinical Trials and Results 5.6.7. Drug - X3 - Global Market Potential 5.6.8. Drug - X3 - 7Ps Analysis 5.7. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X4 5.7.1. Description 5.7.2. Regulatory Milestones 5.7.3. Advantages & Disadvantages 5.7.4. Product Profile & Expected Launch 5.7.5. Clinical Trials and Status 5.7.6. Pivotal Clinical Trials and Results 5.7.7. Drug - X4 - Global Market Potential 5.7.8. Drug - X4 - 7Ps Analysis 5.8. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X5 5.8.1. Description 5.8.2. Regulatory Milestones 5.8.3. Advantages & Disadvantages 5.8.4. Product Profile & Expected Launch 5.8.5. Clinical Trials and Status 5.8.6. Pivotal Clinical Trials and Results 5.8.7. Drug - X5 - Global Market Potential 5.8.8. Drug - X5 - 7Ps Analysis 5.9. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X6 5.9.1. Description 5.9.2. Regulatory Milestones 5.9.3. Advantages & Disadvantages 5.9.4. Product Profile & Expected Launch 5.9.5. Clinical Trials and Status 5.9.6. Pivotal Clinical Trials and Results 5.9.7. Drug - X6 - Global Market Potential 5.9.8. Drug - X6 - 7Ps Analysis 5.10. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X7 5.10.1. Description 5.10.2. Regulatory Milestones 5.10.3. Advantages & Disadvantages 5.10.4. Product Profile & Expected Launch 5.10.5. Clinical Trials and Status 5.10.6. Pivotal Clinical Trials and Results 5.10.7. Drug - X7 - Global Market Potential 5.10.8. Drug - X7 - 7Ps Analysis 6. Global Migraine Drugs Market: Growth and Forecast 6.1. By Value (2012-2016) 6.2. By Value (2017-2022) 7. Global Migraine Drugs Market - Analysis By Type 7.1. Global Migraine Drugs Market, By Type: Breakdown (%) 7.1.1. Global Migraine Drugs Market- By Type: 2016 (%) 7.1.2. Global Migraine Drugs Market By Type: 2022 (%) 7.2. Global Migraine Drugs Market- By Acute 7.2.1. By Value (2012-2016) 7.2.2. By Value (2017-2022) 7.3. Global Migraine Drugs Market- By Prophylaxis 7.3.1. By Value (2012-2016) 7.3.2. By Value (2017-2022) 8. Global Migraine Drugs Market: Country Analysis (U.S, U.K, Japan, France, Italy, Germany, ROW) 8.1. U.S. Migraine Drugs Market, By Value (2012-2022) 8.2. U.K. Migraine Drugs Market, By Value (2012-2022) 8.3. Japan Migraine Drugs Market, By Value (2012-2022) 8.4. France Migraine Drugs Market, By Value (2012-2022) 8.5. Italy Migraine Drugs Market, By Value (2012-2022) 8.6. Germany Migraine Drugs Market, By Value (2012-2022) 8.7. ROW Migraine Drugs Market, By Value (2012-2022) 9. Market Dynamics 9.1. Migraine Drug Market Drivers 9.2. Migraine Drug Market Challenges 10. Company Profiles 10.1. Amgen 10.2. Allergan 10.3. Eli Lilly 10.4. Alder Pharmaceuticals 10.5. Teva Pharmaceuticals 10.6. Vernalis 10.7. Pfizer 10.8. Impax Laboratories 10.9. Glaxo Smithkline

Biosimilars Pipeline Market Size And Share Analysis - Growth Trends And Forecasts (2025-2032)...

The Biosimilars Pipeline Market is set to witness immense growth during the forecast period 2025-2032. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufacturers/...

Orphan Drugs Market Size And Share Analysis - Growth Trends And Forecasts (2025-2032)...

The Orphan Drugs Market is set to witness immense growth during the forecast period 2025-2032. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufacturers/players/...

Canine Dilated Cardiomyopathy Drugs Market Size And Share Analysis - Growth Trends And Forecasts (2025-2032)...

The Canine Dilated Cardiomyopathy Drugs Market is set to witness immense growth during the forecast period 2025-2032. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape,...

Bioengineered Monoclonal Antibodies Protein Drugs Market Size And Share Analysis - Growth Trends And Forecasts (2025-2032)...

The Bioengineered Monoclonal Antibodies Protein Drugs Market is set to witness immense growth during the forecast period 2025-2032. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competit...

Anti-Viral Nucleotide Polymerase Inhibitor Drugs Market Size And Share Analysis - Growth Trends And Forecasts (2025-2032)...

The Anti-Viral Nucleotide Polymerase Inhibitor Drugs Market is set to witness immense growth during the forecast period 2025-2032. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competiti...

Bioengineered Protein Drugs Market Size And Share Analysis - Growth Trends And Forecasts (2025-2032)...

The Bioengineered Protein Drugs Market is set to witness immense growth during the forecast period 2025-2032. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufac...

Chronic Kidney Disease (CKD) Drugs Market Size And Share Analysis - Growth Trends And Forecasts (2025-2032)...

The Chronic Kidney Disease (CKD) Drugs Market is set to witness immense growth during the forecast period 2025-2032. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, ...

Open Angle Glaucoma Pipeline Market Size And Share Analysis - Growth Trends And Forecasts (2025-2032)...

The Open Angle Glaucoma Pipeline Market is set to witness immense growth during the forecast period 2025-2032. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufa...

Synthetic Lethality-Based Drugs and Targets Market Size And Share Analysis - Growth Trends And Forecasts (2025-2032)...

The Synthetic Lethality-Based Drugs and Targets Market is set to witness immense growth during the forecast period 2025-2032. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive la...

Data Pipeline Observability Solutions Market Size And Share Analysis - Growth Trends And Forecasts (2025-2032)...

The Data Pipeline Observability Solutions Market is set to witness immense growth during the forecast period 2025-2032. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscap...